SGRY · Surgery Partners, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - |
| R&D | - | - | - | - | - | - | - | - | - | - |
| SG&A | $39.30M | - | $22.40M | $36.10M | $36.00M | - | $29.20M | $40.30M | $33.20M | - |
| Total Operating Expenses | $745.10M | - | $715.80M | $714.50M | $714.10M | - | $709.50M | $677.30M | $641.40M | - |
| D&A | $38.50M | - | $39.50M | $40.30M | $36.30M | - | $50.20M | $34.80M | $33.70M | - |
| Operating Income | $65.80M | - | $105.70M | $111.70M | $61.90M | - | $60.90M | $84.80M | $76.00M | - |
| Interest Expense | - | - | - | - | - | - | - | - | - | - |
| Income Tax | ($1.20M) | - | $5.50M | ($1.10M) | $0 | - | $4.50M | $4.90M | $4.40M | - |
| Net Income | ($35.90M) | - | ($22.70M) | ($2.50M) | ($37.70M) | - | ($31.70M) | ($15.50M) | ($12.40M) | - |
| EPS - Basic | ($0.28) | - | ($0.18) | ($0.02) | ($0.30) | - | ($0.25) | ($0.12) | ($0.10) | - |
| EPS - Diluted | ($0.28) | - | ($0.18) | ($0.02) | ($0.30) | - | ($0.25) | ($0.12) | ($0.10) | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $182.30M | $239.90M | $203.40M | $250.10M | $229.30M | $269.50M | $221.80M | $213.50M | $185.20M | $195.90M |
| Accounts Receivable | $603.40M | $602.20M | $579.30M | $563.10M | $570.60M | $579.10M | $542.90M | $523.40M | $494.30M | $496.40M |
| Inventory | $100.50M | $96.60M | $92.30M | $87.30M | $88.10M | $88.40M | $82.00M | $80.90M | $77.00M | $75.20M |
| Accounts Payable | $168.60M | $208.70M | $174.60M | $174.90M | $165.00M | $208.70M | $170.80M | $174.00M | $174.10M | $171.80M |
| Current Assets | $1.08B | $1.15B | $1.10B | $1.11B | $1.07B | $1.12B | $1.04B | $1.01B | $895.90M | $895.00M |
| Total Assets | $8.04B | $8.12B | $7.95B | $7.95B | $7.95B | $7.89B | $7.53B | $7.49B | $6.98B | $6.88B |
| Current Liabilities | $581.70M | $615.50M | $586.00M | $573.30M | $569.40M | $624.40M | $575.20M | $551.80M | $523.40M | $523.00M |
| Long-term Debt | - | $3.74B | - | - | - | $3.40B | - | - | - | $2.80B |
| Total Liabilities | - | - | - | - | - | - | - | - | - | - |
| Stockholders' Equity | $1.69B | $1.71B | $1.73B | $1.75B | $1.74B | $1.79B | $1.90B | $1.95B | $1.97B | $1.99B |
| Retained Earnings | ($851.10M) | ($815.20M) | ($800.20M) | ($777.50M) | ($775.00M) | ($737.30M) | ($628.80M) | ($597.10M) | ($581.60M) | ($569.20M) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $11.70M | - | - | - | $6.00M | - | - | - | $40.70M | - |
| Investing Cash Flow | ($13.40M) | - | - | - | ($76.40M) | - | - | - | ($83.10M) | - |
| Financing Cash Flow | ($55.90M) | - | - | - | $30.20M | - | - | - | $31.70M | - |
| CapEx | $16.00M | - | - | - | $22.70M | - | - | - | $21.00M | - |
| Free Cash Flow | ($4.30M) | - | - | - | ($16.70M) | - | - | - | $19.70M | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | - | - | - | - | - | - | - | - | - | - |
| EBITDA margin | - | - | - | - | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - | - | - | - | - |
| Free cash flow margin | - | - | - | - | - | - | - | - | - | - |
| FCF / Net income | 0.12 | - | - | - | 0.44 | - | - | - | -1.59 | - |
| R&D / Revenue | - | - | - | - | - | - | - | - | - | - |
| SG&A / Revenue | - | - | - | - | - | - | - | - | - | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -0.4% | - | -0.3% | -0.0% | -0.5% | - | -0.4% | -0.2% | -0.2% | - |
| Return on equity | -2.1% | - | -1.3% | -0.1% | -2.2% | - | -1.7% | -0.8% | -0.6% | - |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 1.86 | 1.87 | 1.88 | 1.93 | 1.89 | 1.79 | 1.80 | 1.83 | 1.71 | 1.71 |
| Quick ratio | 1.69 | 1.71 | 1.72 | 1.78 | 1.73 | 1.65 | 1.66 | 1.69 | 1.56 | 1.57 |
| Cash ratio | 0.31 | 0.39 | 0.35 | 0.44 | 0.40 | 0.43 | 0.39 | 0.39 | 0.35 | 0.37 |
| Leverage | ||||||||||
| Debt / Equity | - | 2.18 | - | - | - | 1.90 | - | - | - | 1.41 |
| Debt / Assets | - | 0.46 | - | - | - | 0.43 | - | - | - | 0.41 |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - | - | - | - | - |
| Equity multiplier | 4.76 | 4.74 | 4.59 | 4.55 | 4.57 | 4.41 | 3.97 | 3.84 | 3.55 | 3.46 |
| Liabilities / Assets | - | - | - | - | - | - | - | - | - | - |
| Efficiency | ||||||||||
| Asset turnover | - | - | - | - | - | - | - | - | - | - |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | 0.9x | - | 1.6x | 1.6x | 1.7x | - | 2.1x | 1.5x | 1.9x | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | 12.9x | - | 17.6x | 16.9x | 28.3x | - | 34.6x | 23.3x | 32.6x | - |
| Growth | ||||||||||
| Revenue growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | 6.3% | - | 73.6% | 31.7% | -18.6% | - | -26.3% | -13.1% | 63.8% | - |
| Net income growth (YoY) | 4.8% | - | 28.4% | 83.9% | -204.0% | - | -546.9% | - | 50.2% | - |
| EPS growth (YoY) | 6.7% | - | 28.0% | 83.3% | -200.0% | - | -525.0% | - | 50.0% | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | 74.3% | - | - | - | - | - | - | - | -60.8% | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | 17.8% | - |
| Book value growth (YoY) | -3.0% | -4.3% | -8.8% | -10.5% | -11.5% | -9.9% | -5.4% | -3.3% | 0.3% | -0.6% |
Peer comparison
Same SIC group: Services-General Medical & Surgical Hospitals, NEC
Comparing Surgery Partners against the 5 most active filers in the same SIC group.